RU98102187A - APPLICATION OF ALLYLAMINE DERIVATIVES, SUCH AS TERBINAFIN, IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OR ASSOCIATED DISEASES - Google Patents

APPLICATION OF ALLYLAMINE DERIVATIVES, SUCH AS TERBINAFIN, IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OR ASSOCIATED DISEASES

Info

Publication number
RU98102187A
RU98102187A RU98102187/14A RU98102187A RU98102187A RU 98102187 A RU98102187 A RU 98102187A RU 98102187/14 A RU98102187/14 A RU 98102187/14A RU 98102187 A RU98102187 A RU 98102187A RU 98102187 A RU98102187 A RU 98102187A
Authority
RU
Russia
Prior art keywords
pylori infection
infection
compound
treatment
associated diseases
Prior art date
Application number
RU98102187/14A
Other languages
Russian (ru)
Other versions
RU2193402C2 (en
Inventor
Айвен Джеймз Далтон Линдли
Нил Стюарт Райдер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513750.1A external-priority patent/GB9513750D0/en
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU98102187A publication Critical patent/RU98102187A/en
Application granted granted Critical
Publication of RU2193402C2 publication Critical patent/RU2193402C2/en

Links

Claims (9)

1. Применение соединения формулы I
Figure 00000001

где либо R присоединен в положении 1 или 2 нафтильного кольца и представляет собой
Figure 00000002

либо R присоединен в положении 1 и представляет собой
Figure 00000003
фенил или N[(Е)-3-фенил-2-пропенил] -2-пиридинил, в форме свободного основания или фармацевтически приемлемой соли, в изготовлении лекарственного средства для использования в терапии инфекции Helicobacter pylori и ассоциированных заболеваний, таких как гастрит, пептическая язва, язва двенадцатиперстной кишки, атрофия желудка, кишечная метаплазия, неязвенная диспепсия, MALT лимфома, не-ходжкинская лимфома и рак желудка, причем субъект, страдающий от инфекции Н. pylori, не страдает от грибковой инфекции или не лечится от нее.1. The use of the compounds of formula I
Figure 00000001

where either R is attached in position 1 or 2 naphthyl ring and represents
Figure 00000002

either R is attached at position 1 and is
Figure 00000003
phenyl or N [(E) -3-phenyl-2-propenyl] -2-pyridinyl, in the form of a free base or a pharmaceutically acceptable salt, in the manufacture of a medicine for use in the treatment of Helicobacter pylori infection and associated diseases such as gastritis, peptic ulcer, duodenal ulcer, gastric atrophy, intestinal metaplasia, nonulcer dyspepsia, MALT lymphoma, non-Hodgkin's lymphoma and stomach cancer, and the subject suffering from H. pylori infection does not suffer from a fungal infection or is not treated for it. 2. Применение по п.1 соединения формулы I, как определено в п.1, отличающееся тем, что R присоединен в положении 1 и представляет собой
Figure 00000004
в форме свободного основания или фармацевтически приемлемой соли.2. The use according to claim 1 of a compound of formula I, as defined in claim 1, characterized in that R is attached in position 1 and is
Figure 00000004
in the form of a free base or a pharmaceutically acceptable salt. 3. Применение по п.2, отличающееся тем, что соединение находится в форме гидрохлорида. 3. The use according to claim 2, characterized in that the compound is in the form of hydrochloride. 4. Способ лечения инфекции Helicobacter pylori и ассоциированных заболеваний, как определено в п.1, при котором на субъекта, нуждающегося в таком лечении, воздействуют терапевтически эффективным количеством соединения, как определено в п.1, причем субъект, страдающий от инфекции Н. pylory, не страдает от грибковой инфекции или не лечится от нее. 4. A method of treating Helicobacter pylori infection and associated diseases as defined in claim 1, wherein the subject in need of such treatment is affected by a therapeutically effective amount of the compound as defined in claim 1, wherein the subject suffers from H. pylory infection , does not suffer from a fungal infection or is not treated for it. 5. Применение соединения, как определено в п.1 в терапии инфекции Helicobacter pylori и ассоциированных заболеваний, как определено в п.1, причем субъект, страдающий от инфекции Н. pylori, не страдает от грибковой инфекции или не лечится от нее. 5. The use of a compound as defined in claim 1 in the treatment of Helicobacter pylori infection and associated diseases as defined in claim 1, wherein the subject suffering from H. pylori infection does not suffer from a fungal infection or is not treated for it. 6. Агент для использования в терапии инфекции Helicobacter pylori и ассоциированных заболеваний, как определено в п.1, причем субъект, страдающий от инфекции Н. pylori, не страдает от грибковой инфекции или не лечится от нее, содержащий соединение формулы I, как определено в п.1, в форме свободного основания или фармацевтически приемлемой соли вместе с по меньшей мере одним фармацевтически приемлемым носителем или разбавителем. 6. An agent for use in the treatment of Helicobacter pylori infection and associated diseases as defined in claim 1, wherein the subject suffering from H. pylori infection does not suffer from or is not treated with a fungal infection containing the compound of formula I as defined in 1, in the form of a free base or a pharmaceutically acceptable salt together with at least one pharmaceutically acceptable carrier or diluent. 7. Фармацевтическая композиция, адаптированная для использования в терапии инфекции Helicobacter pylori и ассоциированных заболеваний, как определено в п.1, причем субъект, страдающий от инфекции Н. pylori, не страдает от грибковой инфекции или не лечится от нее, которая содержит соединение формулы I в форме свободного основания или фармацевтически приемлемой соли, возможно в сочетании с одним или более чем одним другим активным агентом, и компаундированная, как перорально вводимая капсульная оболочка или питьевой раствор для высвобождения и действия в желудочно-кишечной системе. 7. A pharmaceutical composition adapted for use in the treatment of Helicobacter pylori infection and associated diseases as defined in claim 1, wherein the subject suffering from H. pylori infection does not suffer from a fungal infection or is not treated for it, which contains a compound of formula I in the form of a free base or a pharmaceutically acceptable salt, possibly in combination with one or more other active agents, and compounded, such as an oral capsule sheath or drinking solution for release and action in the gastrointestinal system. 8. Применение по п.1 или 5, способ по п.4, агент по п.6 или композиция по п. 7, отличающиеся тем, что соединение формулы I, как определено в п.1, находится в сочетании с одним или более чем одним другим перорально активным агентом, таким как циметидин, ранитидин, фамотидин, омепразол, метронидазол и сукральфат. 8. The use according to claim 1 or 5, the method according to claim 4, the agent according to claim 6 or the composition according to claim 7, characterized in that the compound of formula I, as defined in claim 1, is in combination with one or more than one other orally active agent, such as cimetidine, ranitidine, famotidine, omeprazole, metronidazole and sucralfate. 9. Способ приготовления лекарственного средства для использования в терапии инфекции Helicobacter pylori и ассоциированных заболеваний, как определено в п.1, причем субъект, страдающий от инфекции Н. pylori, не страдает от грибковой инфекции или не лечится от нее, при котором смешивают соединение, как определено в п.1, возможно в сочетании с одним или более чем одним другим активным агентом, вместе с по меньшей мере одним фармацевтически приемлемым носителем или разбавителем. 9. A method of preparing a drug for use in the treatment of Helicobacter pylori infection and associated diseases as defined in claim 1, wherein the subject suffering from H. pylori infection does not suffer from a fungal infection or is not treated for it, in which the compound is mixed, as defined in claim 1, possibly in combination with one or more other active agents, together with at least one pharmaceutically acceptable carrier or diluent.
RU98102187/14A 1995-07-06 1996-07-05 Application of allylamine derivatives, such as terbinaphin, in manufacturing medicinal preparation for treating helicobacter pylori infection or helicobacter pylori-associated diseases RU2193402C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9513750.1 1995-07-06
GBGB9513750.1A GB9513750D0 (en) 1995-07-06 1995-07-06 Use of allylamines

Publications (2)

Publication Number Publication Date
RU98102187A true RU98102187A (en) 1999-11-10
RU2193402C2 RU2193402C2 (en) 2002-11-27

Family

ID=10777201

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98102187/14A RU2193402C2 (en) 1995-07-06 1996-07-05 Application of allylamine derivatives, such as terbinaphin, in manufacturing medicinal preparation for treating helicobacter pylori infection or helicobacter pylori-associated diseases

Country Status (27)

Country Link
US (1) US5935998A (en)
EP (1) EP0863752B1 (en)
JP (1) JP3680950B2 (en)
KR (1) KR100425401B1 (en)
CN (1) CN1204881C (en)
AT (1) ATE232723T1 (en)
AU (1) AU715270B2 (en)
CA (1) CA2219678C (en)
CY (1) CY2465B1 (en)
CZ (1) CZ289440B6 (en)
DE (1) DE69626301T2 (en)
DK (1) DK0863752T3 (en)
ES (1) ES2192608T3 (en)
GB (1) GB9513750D0 (en)
HK (1) HK1011527A1 (en)
HU (1) HU224311B1 (en)
IL (1) IL122853A (en)
MX (1) MX9710093A (en)
MY (1) MY132436A (en)
NO (1) NO317496B1 (en)
PL (1) PL187704B1 (en)
RU (1) RU2193402C2 (en)
SI (1) SI0863752T1 (en)
SK (1) SK282874B6 (en)
TW (1) TW522011B (en)
WO (1) WO1997002026A1 (en)
ZA (1) ZA965749B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001315D0 (en) * 2000-01-20 2000-03-08 Novartis Ag Organic compounds
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
KR20030066186A (en) * 2002-02-05 2003-08-09 한솔케미언스 주식회사 Process for preparation of Terbinafin
EP1706128B1 (en) * 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
RU2449805C1 (en) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Peptide pharmaceutical composition, based drug for gastroduodenal diseases caused by helicobacter pylori, and method of using it

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2716943C2 (en) * 1976-04-28 1986-08-14 Sandoz-Patent-GmbH, 7850 Lörrach N- (3-Phenyl-2-propenyl) -N- (1-naphthylmethyl) amines, their use and preparation
DE2862103D1 (en) * 1977-08-19 1982-11-18 Sandoz Ag Propenyl amines, processes for their production and pharmaceutical compositions containing them
DE3020113A1 (en) * 1979-06-08 1980-12-18 Sandoz Ag 2- (1-NAPHTHYL) PIPERIDINE DERIVATIVE, THE PRODUCTION THEREOF AND THE USE AS AN ANTIMYCOTIC
ATE10272T1 (en) * 1979-08-22 1984-11-15 Sandoz Ag PROPENYLAMINES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS MEDICINAL PRODUCTS.
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4894375A (en) * 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
CA2020888A1 (en) * 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
DE4317449A1 (en) * 1993-05-19 1994-11-24 Asche Ag Pharmaceutical composition for the treatment of disorders of the gastrointestinal tract

Similar Documents

Publication Publication Date Title
RU2143899C1 (en) Pharmaceutical composition, method of preparation thereof, and treatment method
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
DE69400493D1 (en) Use of rifaximin and rifaximin-containing pharmaceutical compositions for the treatment of gastric dyspepsia caused by Helicobacter pylori
RU93058555A (en) Quinuclidine derivatives, a method for their production, a pharmaceutical composition, a method for the treatment or prevention
RU99128072A (en) NEW S-OMEPRAZOL FORM
CA2077653A1 (en) Phenyl butyl nitrone compositions for prevention of gastric ulceration
RU99100397A (en) NEW CONNECTIONS
RU98102187A (en) APPLICATION OF ALLYLAMINE DERIVATIVES, SUCH AS TERBINAFIN, IN THE MANUFACTURE OF A MEDICINE FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTION OR ASSOCIATED DISEASES
IL99471A (en) Pharmaceutical compositions for treating helicobacter bacteria infections containing 5-fluoromethoxy-2-(3,4-dimethoxy-2-pyridyl)methylsulphinyl)-1h-benzimidazole and salts thereof in combination with an antimicrobial agent
AU8424091A (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
EP1073436A1 (en) IMPROVED METHOD FOR ERADICATION OF $i(HELICOBACTER PYLORI)
RU95105169A (en) Method of treatment of infectious diseases caused by helicobacter pilori
RO88420A (en) PROCEDURE FOR THE PREPARATION OF PIROXICAN BASIC BATCHES EMPTY ON PHARMACEUTICAL SUPPORTS
WO2003095453A1 (en) Compounds against helicobacter activity
RU2003133155A (en) METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTIONS IN THE STOMACH
RU96100758A (en) NEW ACTIVE CONNECTIONS
AP598A (en) Metronidazole combinations.
EP0865286A1 (en) Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders
ATE270T1 (en) NEW N1-BENZOYL-N2-PHENYL-1,3-DIAMINOPROPAN-2-OLS AND THEIR SALTS; PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS.
JPH08337529A (en) Therapeutic agent for disease in superior digestive tract
JP2000080031A (en) Antimicrobial agent
CA2401112A1 (en) Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
AU3400699A (en) Improved method for eradication of Helicobacter Pylori
TH44437A (en) Uses of allillamine